Following positive research findings , retatrutide, a innovative peptide therapy for managing non-insulin dependent hyperglycemia , has received official approval from the Drug and Products Agency (MHRA ). Limited availability is currently expected via dedicated weight-related centres and certain National Health Service organisations in the timefra